Abstract: https://www.acpjournals.org/doi/10.7326/M23-0192
Editorial: https://www.acpjournals.org/doi/10.7326/M23-1991
FREE Summary: https://www.acpjournals.org/doi/10.7326/M23-0005
Researchers from Charite – Universitätsmedizin Berlin, Berlin, Germany conducted a pooled analysis of five randomized controlled trials with 2-year interventions to evaluate the effects of low-dose glucocorticoid treatment in RA. The researchers found that use of low-dose glucocorticoids was associated with a 1.1 kilogram weight increase compared to a control. They observed no significant differences in blood pressure between groups.
An accompanying editorial by David Fernandez, MD, PhD of the Hospital for Special Surgery, New York, New York says that the risks of low-dose glucocorticoid therapy may be smaller and more manageable than they may appear based on observational studies. He notes that the 2-year timespan of the studies may not fully evaluate the effect of weight gain and hypertension because those effects may manifest over decades. However, the findings provide a more quantifiable assessment of the potential adverse effects of steroid therapy than had existed previously and will be helpful to providers and patients as they decide on the relative risks and benefits of glucocorticoids as part of their therapy plan.